此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (CA2969417) BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY

专利局 : 加拿大
申请号: 2969417 申请日:
公布号: 2969417 公布日: 09.06.2016
公布类型: A1
专利合作条约参考号: 申请号:PCTUS2015063928;公布号: 单击查看数据
国际专利分类:
A61K 39/395
A61K 31/33
A 人类生活必需
61
医学或兽医学;卫生学
K
医用、牙科用或梳妆用的制剂
39
含有抗原或抗体的医药配制品
395
抗体;免疫球蛋白;免疫血清,例如抗淋巴细胞血清
A 人类生活必需
61
医学或兽医学;卫生学
K
医用、牙科用或梳妆用的制剂
31
含有机有效成分的医药配制品
33
杂环化合物
申请人: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
DANA-FARBER CANCER INSTITUTE, INC.
发明人:
优先权数据: 62/088,327 05.12.2014 US
62/106,885 23.01.2015 US
标题: (EN) BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY
(FR) INHIBITEUR DE BROMODOMAINES COMME ADJUVANT EN IMMUNOTHERAPIE ANTICANCEREUSE
摘要: front page image
(EN) Inhibition of bromodomain proteins in antigen presenting cells is shown herein to be more inflammatory, to display lower expression of the immunosuppressive molecule PDL1, and to be capable of restoring the responsiveness of tolerant T-cells. Therefore, disclosed is a method for promoting T-cell activation during cancer immunotherapy in a subject that involves administering to a subject undergoing cancer immunotherapy a composition comprising a bromodomain inhibitor. Also disclosed is a method for treating cancer in a subject, comprising co-administering to the subject a bromodomain inhibitor and an immunostimulatory agent.